FORT WORTH, Texas / May 06, 2024 / Business Wire / Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced continued support for the global charity Mercy Ships with the donation of solutions from the recently announced XT Amplify program.
The largest non-governmental hospital fleet in the world, Mercy Ships travels to developing nations to provide sorely needed, quality healthcare for underserved patients. Each year, the organization sends out hospital ships filled with volunteer medical professionals to provide life-changing procedures free of charge to people who often have little or no access to medical care.
“Omnicell’s continued support enables our volunteer hospital crew to provide high quality care to our patients by ensuring access to Omnicell’s latest medication management technology,” said Jonathan Dyson, Director of IT Strategy and Governance. “This partnership will forever impact the lives and communities of those we serve."
Omnicell has supported the mission of Mercy Ships through technology donations and technical support since 2017. With the recent donation of XTExtend, the Company will provide a comprehensive console swap for previously implemented XT automated dispensing systems to enhance security and improve the user experience.
“Omnicell and Mercy Ships were both founded on the idea of finding a better way,” said Kathleen Nemeth, senior vice president of Investor Relations and liaison to Mercy Ships for Omnicell. “We’re proud to support their mission to deliver care to those most in need, to help provide equitable access to innovative pharmacy care solutions for all patients worldwide, strengthening the global healthcare infrastructure.”
The Mercy Ships donation is part of Omnicell’s broader commitment to positively transforming healthcare and improving the communities where we operate and serve through programs like Omnicell Cares, our charitable efforts program, and the Company’s Environmental, Social, and Governance initiatives.
About Mercy Ships
Mercy Ships uses hospital ships to deliver free, world-class healthcare services, capacity building and sustainable development to those with little access in the developing world. Founded in 1978 by Don and Deyon Stephens, Mercy Ships has worked in more than 70 countries providing services valued at more than $1.3 billion, treating more than 2.61 million direct beneficiaries. The Africa Mercy is crewed by 400 volunteers from up to 40 nations, an average of 1000 each year. Professionals including surgeons, dentists, nurses, healthcare trainers, teachers, cooks, seamen, engineers, and agriculturalists donate their time and skills to the effort. With offices in 16 nations, Mercy Ships seeks to transform individuals and serve nations one at a time. For more information visit www.mercyships.org.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Last Trade: | US$44.98 |
Daily Change: | 0.59 1.33 |
Daily Volume: | 2,325,959 |
Market Cap: | US$2.080B |
December 09, 2024 November 18, 2024 October 30, 2024 September 25, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB